CASP3 and neoplasm: As depicted in Fig. 5D–F, the Immunohistochemical results showed that the combination treatment (Cisplatin + siSLPI) exhibited the lowest level of Ki67, which is strictly associated with tumor growth, and the highest c-caspase-3 level an apoptosis biomarker.